John Kiely Sells 32,000 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock

John Kiely, Director of Amneal Pharmaceuticals (NASDAQ:AMRX), sold 32,000 shares at an average price of $9.23 on August 27, totaling $295,360. This sale reduced his holdings by 12.43%, leaving him with 225,433 shares valued at approximately $2.08 million. The transaction was disclosed to the SEC. Amneal's stock opened at $9.55, with a market cap of $3 billion and a PE ratio of 955.96. Analysts have a "Buy" rating on the stock, with an average target price of $11.60.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) Director John Kiely sold 32,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total transaction of $295,360.00. Following the completion of the transaction, the director owned 225,433 shares of the company's stock, valued at approximately $2,080,746.59. This trade represents a 12.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Amneal Pharmaceuticals Price Performance

6 reasons to buy Teva Pharmaceuticals stock sooner than later

Shares of NASDAQ AMRX opened at $9.55 on Friday. The company has a 50 day simple moving average of $8.49 and a 200 day simple moving average of $8.05. The firm has a market cap of $3.00 billion, a PE ratio of 955.96 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $9.79.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Wall Street Zen lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on shares of Amneal Pharmaceuticals in a report on Friday, June 6th. They set a "buy" rating and a $12.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $11.60.

Read Our Latest Stock Analysis on AMRX

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds have recently bought and sold shares of AMRX. Nuveen LLC bought a new stake in Amneal Pharmaceuticals during the 1st quarter valued at $19,581,000. Rubric Capital Management LP increased its stake in Amneal Pharmaceuticals by 9.1% during the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company's stock valued at $94,737,000 after purchasing an additional 974,355 shares in the last quarter. Woodline Partners LP increased its stake in Amneal Pharmaceuticals by 165.2% during the 1st quarter. Woodline Partners LP now owns 1,504,095 shares of the company's stock valued at $12,604,000 after purchasing an additional 937,035 shares in the last quarter. Vanguard Group Inc. increased its stake in Amneal Pharmaceuticals by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock valued at $132,092,000 after purchasing an additional 920,758 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Amneal Pharmaceuticals by 51.3% during the 1st quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company's stock valued at $21,759,000 after purchasing an additional 880,471 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Five stocks we like better than Amneal Pharmaceuticals
Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
Overbought Stocks Explained: Should You Trade Them?
Snowflake’s Snowballing Business and Robust Stock Price Outlook
3 Small Caps With Big Return Potential
Chevron Stock Outlook: Dividend Growth Meets Inflation

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Amneal Pharmaceuticals?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Amneal Pharmaceuticals and related companies.

From Our Partners